OSR (OSRH) Revenue & Revenue Breakdown
OSR Revenue Highlights
0
Latest Revenue (Q)
$1.14M
OSR Revenue by Period
OSR Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | - | 100.00% |
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | - |
OSR generated - in revenue during NA 2024, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
OSR Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-06-30 | $1.14M | 49.16% |
| 2025-03-31 | $761.27K | -131.78% |
| 2024-12-31 | $-2.40M | -381.84% |
| 2024-09-30 | $849.80K | 2.18% |
| 2024-06-30 | $831.67K | -8.63% |
| 2024-03-31 | $910.23K | -137.60% |
| 2023-12-31 | $-2.42M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | - |
OSR generated $1.14M in revenue during Q2 2025, up 49.16% compared to the previous quarter, and up 124.75% compared to the same period a year ago.
OSR Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ADAP | Adaptimmune Therapeutics | $178.03M | $7.29M |
| LPCN | Lipocine | $11.20M | $114.57K |
| ANL | Adlai Nortye | $5.00M | $2.50M |
| BLRX | BioLineRx | $4.80M | $6.86M |
| ERNA | Ernexa Therapeutics | $582.00K | - |
| EDSA | Edesa Biotech | - | - |
| GOVX | GeoVax Labs | - | $852.28K |
| APLM | Apollomics | - | - |
| OSRH | OSR | - | $1.14M |
| THAR | Tharimmune | - | - |
| PMN | ProMIS Neurosciences | - | - |